GBR 830

Drug Profile

GBR 830

Alternative Names: GBR830

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Monoclonal antibodies
  • Mechanism of Action OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Autoimmune disorders
  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2017 Glenmark Pharmaceuticals plans a phase IIb trial for Atopic dermatitis in H1 2018
  • 31 Jul 2017 Pharmacodynamics and adverse events data from a phase IIa trial in Atopic dermatitis released by Glenmark
  • 01 Jun 2017 Glenmark Pharmaceuticals completes a phase IIa trial in Atopic dermatitis in USA and Canada (NCT02683928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top